trending Market Intelligence /marketintelligence/en/news-insights/trending/ZvnEHz-0lEv7x_iLfnjLbA2 content esgSubNav
In This List

Regeneron, ISA Pharmaceuticals enter cancer drug collaboration

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Regeneron, ISA Pharmaceuticals enter cancer drug collaboration

Regeneron Pharmaceuticals Inc. will develop its cemiplimab in combination with ISA Pharmaceuticals BV's ISA101 for cervical and head-and-neck cancer under a new agreement.

As part of the deal, Regeneron will make an upfront payment and an equity investment in exchange for an option to an exclusive, global license for ISA101. Upon exercising the exclusivity option for ISA101, ISA may receive milestone payments and tiered royalty payments contingent on regulatory approvals, sales and additional indications. Further financial details were not disclosed.

The companies will jointly fund and conduct the clinical trials.

Cemiplimab, also known as REGN2810, is a PD-1 antibody being jointly developed by Regeneron and Sanofi. The medicine is being studied as a single therapy in multiple tumor types including skin, lung and cervical cancers, and in other therapeutic combinations.